Water, Centella Asiatica Extract (13.5%), Butylene Glycol, Dipropylene Glycol, Nelumbo Nucifera Extract, Artemisia Annua Extract, Oryza Sativa (Rice) Extract, Saccharomyces Ferment, Niacinamide (1,000ppm), Glutathione (1,000ppm), Solanum Melongena (Eggplant) Fruit Extract, Melaleuca Alternifolia (Tea Tree) Leaf Extract, Hydrolyzed Collagen, Beta-Glucan, Hippophae Rhamnoides Fruit Extract, Sodium Hyaluronate, Madecassic Acid, Asiaticoside, Asiatic Acid, Squalane, Caprylic/Capric Triglyceride, Hydrogenated Lecithin, Glyceryl Stearate, Cholesterol, Propanediol, Disodium EDTA, Glyceryl Acrylate/Acrylic Acid Copolymer, Cellulose Gum, Xanthan Gum, Inulin, Cellulose, Glucose, Fructose, Polyglucuronic Acid, Hydroxyethyl Urea, Ethylhexylglycerin, Hydroxyacetophenone, Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Taurate Copolymer, Glycerin, Dipotassium Glycyrrhizate, 1,2-Hexanediol, Carbomer, Arginine
The investigation of peptides from enzymic hydrolysates
Moreover, in light of the growing evidence demonstrating the benefits of incretin-based therapies on both metabolic health and cardiovascular diseases, regulatory agencies such as the Food Drug Administration (FDA) and the European Medicines Agency (EMA) have approved their use for type 2 diabetes, reduction of cardiovascular risk and for chronic weight management in patients with morbid obesity [5,6,7,8]
Finland Research in animal models using both peptides is anticipated to reveal enhanced benefits without dramatically increasing adverse effects
